#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they have become resistant to the EGFR-targeting tyrosine kinase inhibitor. In ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.